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Triggering RNA interference (RNAi), in particular, has [2,3]. However, the biomedical utility of the synthetic
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http://www.biosignaling.com/content/11/1/88disease [9,10]. These impediments can be overcome by
using natural carriers of exogenous siRNA to human
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Full list of author information is available at the end of the articlebecome one of the most widely used techniques for bio-
medical applications [4-6]. RNAi uses a mechanism of
posttranscriptional sequence specific gene silencing by
processing double-stranded RNAs into small-interfering
RNAs (siRNAs) used as part of the RNA-induced silen-
cing complex to selectively cleave target mRNA [7].
siRNAs is limited by several RNA structure-related fac-
tors such as the negative charge (uptake by cells that
also have a negatively charged surface) and instability in
the blood circulation (non-modified siRNAs have a very
short half-life in the blood stream, mostly because of
degradation by nucleases) [9]. Another major barrier is
immunogenicity of the synthetic siRNAs or delivery
vehicle, especially if repeated dosing is needed to treat* Correspondence: filatov@omrb.pnpi.spb.ru
1Division of Molecular and Radiation Biophysics, SFBI Petersburg Nucleartechnologies have been significantly intensified [1-3].might be useful in gene cancer therapy to deliver therapeutic short interfering RNA (siRNA) to the target cells.
Despite the promise of RNA interference (RNAi) for use in therapy, several technical obstacles must be overcome.
Exogenous siRNA is prone to degradation, has a limited ability to cross cell membranes and may induce an immune
response. Naturally occurring RNA carriers, such as exosomes, might provide an untapped source of effective
delivery strategies.
Results: This study demonstrates that exosomes can deliver siRNA to recipient cells in vitro. The different strategies
were used to introduce siRNAs into human exosomes of various origins. The delivery of fluorescently labeled siRNA
via exosomes to cells was confirmed using confocal microscopy and flow cytometry. Two different siRNAs against
RAD51 and RAD52 were used to transfect into the exosomes for therapeutic delivery into target cells. The
exosome-delivered siRNAs were effective at causing post-transcriptional gene silencing in recipient cells. Moreover,
the exosome-delivered siRNA against RAD51 was functional and caused the massive reproductive cell death of
recipient cancer cells.
Conclusions: The results strongly suggest that exosomes effectively delivered the siRNA into the target cells. The
therapeutic potential of exosome-mediated siRNA delivery was demonstrated in vitro by the strong knockdown of
RAD51, a prospective therapeutic target for cancer cells. The results give an additional evidence of the ability to use
human exosomes as vectors in cancer therapy, including RNAi-based gene therapy.
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Background
The use of small interfering RNAs to induce gene silen-
cing has opened a new avenue in drug discovery. In the
past decade, efforts to develop RNA-based therapeutic
After the discovery that synthetic siRNAs can be exo-
genously introduced into cells to activate RNAi [8], this
approach has become a powerful method for selective
suppression of specific genes of interest in different spe-
cies, showing potential for use in cancer therapeuticsExosomes are natural car
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cells. Naturally occurring RNA carriers, such as exo-
somes, might provide an untapped source of effective
delivery strategies [11].
Exosomes are nano-sized vesicles (30–120 nm in size)
produced by many cell types, including dendritic cells
(DC), B cells, T cells, mast cells, epithelial cells and
tumor cells [12-15]. These vesicles are formed by inward
budding of late endosomes and are then released to the
extracellular environment upon fusion with the plasma
membrane [15]. They have been detected in body fluids
such as peripheral blood, urine, malignant effusions and
bronchoalveolar lavage fluid [12,14,15]. It has been
shown that these vesicles are involved in signal transduc-
delivered siRNA against RAD51 was also functional and
caused the massive reproductive cell death of recipient
cells. These findings suggest that exosomes derived from
human cells can be utilized in gene cancer therapy to
provide target cells with heterologous nucleic acids such
as therapeutic siRNAs.
Results
Introduction of siRNA into exosomes and delivery of
heterologous siRNAs to recipient cells via exosomes
Exosomes originating from HeLa and ascites were isolated
by ultracentrifugation, as described earlier [22]. Size deter-
mination of isolated exosomes was performed using a
t a
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lopment [12,15]. In 2007, it was demonstrated that
exosomes derived from various cell types contain a sub-
stantial amount of RNA (mainly mRNA and microRNA)
[16]. More importantly, the exosome vesicles shuttle
RNA between cells, an activity which served as a novel
means of cell-to-cell communication [12,17]. The RNA
present in exosomes was therefore termed exosomal
shuttle RNA (esRNA) [17]. As exosomes naturally carry
RNA between cells, it has been speculated that this
property might be useful in gene therapy, in which a
vector is used to deliver therapeutic nucleic acids to the
patient’s target cells [18-20]. In this report, we examined
whether human exosomes can deliver exogenous nucleic
acids to recipient cells in vitro.
In 2008, we investigated survivability of human cells
and their ability to pass through the cell cycle after sup-
pressing the homologous recombination genes by gene-
specific siRNAs [21]. We demonstrated that in most
cancer cell types studied the decrease in the RAD51 pro-
tein level induced cell accumulation in S and G2 phases
of the cell cycle and ultimately led to the massive repro-
ductive cell death. Our data pointed to RAD51 as a po-
tential target for repressing the growth of abnormally
proliferating cells [21]. Here, we show that the exosome-
Figure 1 Characterization of exosomes originating from malighnan
were determined using a Microtrac S3500 particle analyzer. B, exosomes ob
5×5 micrometers.Microtrac S3500 particle analyzer (Microtrac Inc) accor-
ding to the manufacturer’s instructions (Figure 1A). The
ultracentrifuge pellets of exosomes contained spherical
particles that were in accordance with the exosome size
range described earlier [12,15,22]. To estimate the homo-
geneity of the particles the atomic force microscopy
method was used. The exosomes appeared as homoge-
neous circular bulging vesicular structures (Figure 1B).
We also confirmed the presence of exosomal marker pro-
teins HLA-ABC and CD63 [15] on the surface of these
vesicles by dot blot analysis.
Next, we investigated the possibility of loading exo-
somes with exogenous cargoes using chemical treatment.
As chemical transfection for membrane particles at the
nanometer scale is not well-characterized, nonspecific
Alexa flour 488 labeled siRNA (siRNA AF488) was used
for the empirical optimization of the protocol. To exa-
mine the efficiency of chemical loading of exosomes,
siRNA AF488 was mixed with Lipofectamine to allow
for the formation of complexes (siRNA embedded in
lipid micelles), which was then added to the exosomes
and incubated for 30 min at RT. The mixture was
purified for 3-5 times by washing and ultra-filtration
through a 100-kDa filter to eliminate the excess of free
siRNA as well as siRNA embedded into the micelles
scitic fluid. A, the sizes of all particles in the ultracentrifuge pellet
served under atomic force microscopy (AFM), area scan is
Figure 2 In vitro delivery of fluorescently labeled siRNA via
chemically loaded exosomes. The recipient cells were treated for
24 h with exosomes loaded with Lipofectamine-formulated siRNA and
washed several times through a 100-kDa filter (Exo + siRNA + LP + WF).
The sample prepared in identical way but without adding of
exosomes was used (siRNA + LP + WF) as a control. The cells were
also transfected with siRNA by standard procedure (siRNA + LP).
A, flow cytometry analysis of HeLa cells transfected by siRNA.
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siRNA were co-cultured with the recipient cells for 24 h
in order to transfect cells with the heterologous siRNA.
High delivery efficiency of siRNA by exosomes to reci-
pient cells was confirmed by confocal microscopy and
flow cytometry (Figure 2A,B). The recipient cells were
also transfected with siRNA AF488 treated with Lipo-
fectamine (siRNA + LP) in usual manner and after
purifying for several times through a 100-kDa filter as
exosomal samples (siRNA + LP + WF). The results from
flow cytometry and confocal microscopy showed that
the fluorescence signal of the siRNA could be detected
only in the cells transfected usually (siRNA + LP), as ex-
pected (Figure 2A,D). But no fluorescence signal was
detected in control cells incubated with washed and
ultra-filtrated transfection complexes (siRNA + LP +
WF) (Figure 2A,C), confirming that the purification
procedure used was sufficient to remove all non-
associated with exosomes siRNA from the samples.
Thus, the results indicate the possibility of siRNA deli-
very into cells by exosomes in the presence of Lipofecta-
mine. But, as siRNA embedded into the micelles could
unspecifically be attached to the exosomes, it was indis-
tinguishable whether the exosomes or the micelles
of chemical transfection finally delivered exogenous
nucleic acids to cells.
To examine the possibility to input siRNA into exo-
somes in principle we used the fluorescently labeled self-
delivering sdRNA. Self-deliverable RNA molecules do
not require any transfection reagent, vehicle or special
cell treatment. The sdRNA was mixed with exosomes,
incubated 30 min at RT and then the exosome vesicles
were purified using 3-5 times washing and ultrafiltration
through a 100-kDa filter (Amicon ultra, Millipore) to
eliminate the excess of free sdRNA (Exo + sdRNA +
WF). As a control the sample prepared in identical way
without exosomes was used (sdRNA + WF). Then both
samples were co-cultured with the recipient cells for
24 h. The cells were also transfected with sdRNA in
usual manner (sdRNA). The results from flow cytometry
and confocal microscopy showed that the fluorescent
signal of sdRNA was indeed associated with presence of
exosomes (Figure 3A-D). SdRNA could not be detected
in the cells co-cultured with control sample without exo-
somes, confirming that the excess of free sdRNA was de-
pleted by purifying (Figure 3C). In summary, the results
strongly suggest that the approach used was successful
at introducing the heterologous siRNAs into the exo-
somes and at delivery of the siRNAs to recipient cells via
exosomes.
Exosome-delivered siRNA is functional in recipient cells
Given that exosomes from HeLa and ascites could act
as a carrier to deliver nonspecific heterologous genetic
B-D, representative images of HeLa cells 24 h after transfection.
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specific siRNAs delivered via exosomes to cells would
down-regulate the expression of target genes and, if so,
whether the exosome-delivered siRNA would be func-
tional in recipient cells. Therefore, we targeted RAD51 and
RAD52 genes by specific siRNAs delivered via exosomes
to HeLa and HT1080 cells to evaluate the therapeutic po-
tential of this technology. The RAD51 recombinase exe-
cutes the central functions in homologous recombination:
the search for a homologous template DNA and the
formation of the joint heteroduplex molecule between the
damaged DNA and the undamaged template [23]. In
addition to RAD51, homologous recombination requires
the coordinated action of a number of other proteins
of homologous recombination, including RAD52, which
can bind DNA ends and anneal complementary single-
stranded DNA molecules [24]. The role of homologous
recombination in the maintenance of stable genome and
viability of somatic mammalian cells is still under investi-
gation. We have shown previously that depression of the
RAD51 gene function leads to the massive reproductive
death of human cancer cells in the absence of genotoxic
injuries [21]. Our data demonstrated that the significant
down-regulation of RAD51 but not RAD52 protein by the
specific siRNA resulted in S/G2 cell cycle blocks. In most
of the cancer cell lines such blocks resulted in dramatic
decrease in cell viability accompanied by apoptosis or irre-
versible loss of their ability to proliferate. Therefore, we
pointed to RAD51 as a potential target to depress the ab-
normally proliferating cells [21]. Here RAD51 and RAD52
Figure 3 Transfection of HeLa cells by fluorescently labeled
self-delivering sdRNA via exosomes. The recipient cells were
treated for 24 h with exosomes loaded with the sdRNA and washed
several times through a 100-kDa filter (Exo + sdRNA + WF). The
sample prepared in identical way but without adding of exosomes
was used (sdRNA + WF) as a control. The cells were also transfected
with sdRNA by standard procedure (sdRNA). A, flow cytometry
analysis of HeLa cells transfected by sdRNA. B-D, representative
images of HeLa cells 24 h after transfection.were knockdown by specific siRNAs in HeLa and HT1080
cells via genotoxic delivery by exosomes derived from
HeLa and ascitic fluids. Both cell lines were co-cultured
with exosomes chemically loaded with the RAD51 or
RAD52 siRNA for 72-96 h. Western blot analysis showed
a considerable reduction in both RAD51 and RAD52
protein levels in cells as after transfection with specific
siRNAs via exosomes and after siRNA standard cell trans-
fection with Lipofectamine (Additional file 1: Figure S1A).
Moreover the recruitment of RAD51 at double-strand
breaks induced in HeLa cells by ionizing radiation was
reduced in cells treated by exosomes loaded with anti-
RAD51 siRNA (Additional file 1: Figure S1B).
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HeLa cells after RAD51 and RAD52 depletion by two ways: by direct spe
with siRNA exosomes (Exo + siRNA + LP + WF). The survival of the non-Next we examined the colony forming ability of
RAD51 or RAD52 knocked down cells. The total amount
of colonies was counted in 5-7 days after siRNA was
added (Figure 4). Standard transfection with siRNA-
antiRAD51 resulted in a significant decrease of HeLa
and HT1080 cell survival (siRNA + LP). At the same
time transfection with siRNA-antiRAD52 had no effect
on the cell survival. The same results were observed for
the cells transfected by the siRNAs via exosomes (Exo +
siRNA + LP + WF). Neither Lipofectamine alone (LP)
nor exosomes alone (Exo) nor purified by washing and
filtering siRNAs samples (siRNA + LP + WF) had sig-
nificant effect on the cell survival.
We also examined the influence of the RAD51 protein
on the cell cycle parameters. As shown in Figure 5A,
silencing of the RAD51 gene via the siRNA loaded
exosomes during 24-48 h induced the accumulation of
S-phase and G2-phase cells. More prolonged RAD51
siRNA transfection via exosomes (72 h) caused the block
of the recipient cells mainly in the G2/M phase and
apoptotic cells death, which was indicated by high de-
gree of cell DNA degradation (Figure 5A). Apoptosis
was also studied by flow cytometry with mitochondrial
membrane potential and membrane integrity fluoro-
chromes. Both DiOC6(3)/PI and Yo-Pro-1/PI double
staining flow cytometry showed that the apoptotic rate
standard error of the mean (SE) of at least three independent experiments.
co-culturing with ascites-derived exosomes (upper row) or HeLa exosomes
recipient cells.o dramatic decrease of viability of human cells. A, the survival of
ic siRNA chemical transfection (siRNA + LP) and by chemically loaded
nsfected cells was assumed as 100% (control). Error bars represent theof HeLa cells transfected by RAD51 siRNA via exosomes
was increased compared with that in the control cells
(Figure 5B,C). In addition, cell morphology was deter-
mined in RAD51 depleted cells. Figure 5D shows the
morphology of HeLa cells stained with Hoechst 33342.
The confocal images showed that control cells possessed
intact nuclei. The RAD51 siRNA transfection via exo-
somes caused the formation of degraded nuclei, mem-
brane blebbing and clear apoptotic bodies (Figure 5D).
Thus, exosomes from HeLa and ascites were able to
deliver heterologous siRNAs to human cells. Impor-
tantly, the exosome-delivered RAD51 siRNA was func-
tional and caused post-transcriptional gene silencing,
induced accumulation of the cells in S and G2/M phases
of cell cycle and resulted in recipient cell death. Interes-
tingly, the exosomes from different ascites were able to
deliver heterologous siRNAs to human cultured cells
such as HeLa or HT1080 cells (Figure 4B). This observa-
tion indicates the nonspecific ability of the cells to cap-
ture alien vesicles.
As mentioned above, we could not exclude adhesion
of siRNA embedded into the micelles on the surface of
exosomes in the presence of Lipofectamine. However,
the location of siRNA outside of exosomes would lead
to problems in delivery of safe siRNA in vivo. Therefore,
electroporation was examined as a means of introducing
B, the example of clonogenic cell survival of the HeLa cells after
(bottom row) which act as a carrier to deliver specific siRNAs to
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optimal parameters for transferring siRNA into exo-
somes by electroporation, siRNA against RAD51 was
packaged into exosomes derived from HeLa cells. Sur-
vival of the cells after co-culturing with electroporated
exosomes was used as a test system to optimize the
transfection efficiency. The results shown in Figure 6
provide evidence that the heterologous siRNA was intro-
duced into exosomes by electroporation. Summing up
the data, we can assume that exosomes effectively
Figure 5 Exosome-delivered RAD51 siRNA induced accumulation of c
recipient cells. A, Cell cycle distribution of HeLa cells treated by RAD51 siR
staining revealed typical cell cycle profiles. It was possible to identify G0/G1
population. The fraction of cells in each cell cycle phase is indicated at the
potential and plasma membrane integrity fluorochromes after RAD51 depl
exosomes loaded by RAD51 siRNA. DiOC6(3)/PI double staining flow cytom
(C). D, the cells incubated with exosomes loaded by RAD51 siRNA were co
fragmentation with the Hoechst 33342 staining.delivered the siRNA into the target cells, causing select-
ive genes silencing and leading to reproductive cancer
cell death by knockdown of RAD51.
Discussion
The identification of extracellular phospholipid vesicles as
conveyors of cellular information has created excitement
in the field of drug delivery [12]. Biological therapeutics,
including short interfering RNA are prone to degradation,
have limited ability to cross biological membranes, and
ells in G2/M phase of cell cycle and resulted in apoptosis of the
NA via exosomes the indicated time. Examination of Hoechst 33342
peak, G2/M peak, S phase and dead/apoptotic cells (Ap) as a sub-G1
top. B and C, cytometric analyses of mitochondrial transmembrane
etion. HeLa cells were incubated for 72 h with or without (control)
etry analyses (B). Yo-Pro-1/PI double staining flow cytometry dot plots
nfirmed to be dead or apoptotic by microscopy observation of nuclear
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HeLa cells were grown with exosomes loaded with RAD51 siRNA by
electroporation (Exo + siRNA electroporated). Non-targeted cells
were used as negative control (control) in addition to cells grown
with non-electroporated mixture of anti-RAD51 siRNA and
exosomes (Exo + siRNA). The introduction of siRNA into exosomes
was evaluated using a survival analysis of HeLa cells after 5-7 days
of co-culturing with RAD51 siRNA electroporated exosomes as
compared to non-electroporated mixture of siRNA and exosomes.
The survival of the non-transfected cells was assumed as 100%.
Error bars represent the standard error of the mean (SE) of at least
three independent experiments.may elicit immune responses [3]. Therefore, delivery sys-
tems for such drugs are under intensive investigation [25].
Exploiting extracellular vesicles as carriers for biological
therapeutics is a promising strategy to overcome these
issues and to achieve efficient delivery to the cytosol of
target cells [19]. Exosomes are a well-studied class of
extracellular vesicles known to carry proteins and nucleic
acids, making them especially suitable for such strategies.
Exosomes and microvesicles are naturally adapted for the
transport and intracellular delivery of proteins and nucleic
acids. This makes them particularly attractive for the de-
livery of pharmaceutical proteins and nucleic acids, such
as siRNA [19,25]. Intracellular delivery of siRNA is a chal-
lenging task, given that naked siRNAs are rapidly de-
graded in the circulation, their size and negative charge
limits membrane passage and cellular uptake, some siRNA
sequence motifs may elicit undesired immune responses,
and targeting to specific tissues and cells is required to re-
duce adverse effects caused by off-target silencing [26,27].
Encapsulation of nucleic acid-based therapeutics in en-
dogenous transporting vesicles is a promising novel stra-
tegy to overcome most of these delivery issues. Exosomes
may be most suitable for such strategies, because they are
small (30-120 nm), relatively homogenous in size, and well
studied. Their size is advantageous for their use as drug
delivery systems, because this allows them to evade rapid
clearance by the mononuclear phagocyte system andenhances passage through fenestrations in the vessel wall,
as might occur during inflammation [28].
The successful use of exosomes for the targeted delivery
of siRNA has been recently demonstrated by Alvarez-
Erviti et al. [29]. They harvested dendritic cells from mice
and transfected them to express the neuronal targeting
ligand, RVG, coupled to the exosomal membrane protein,
Lamp2b. This protein was expressed by the cells and
incorporated in secreted exosomes. The exosomes were
harvested, purified, and loaded with siRNA against an
important protein in Alzheimer pathogenesis (BACE1) by
electroporation. When the modified exosomes were in-
jected intravenously in wild-type mice, a 60% decrease of
BACE1 mRNA in the brain cortex was observed after
3 days. Moreover, no increase in serum interleukin-6,
interferon gamma-induced protein 10, tumor necrosis
factor alpha and interferon alpha concentrations was ob-
served after injection of the exosomes, suggesting that the
modified exosomes were immunologically inert. The bio-
technological approach to create exosome-based delivery
systems used by Alvarez-Erviti et al. was the first demon-
stration of an exosome-based drug delivery system which
showed efficient in vivo delivery of siRNA [29]. In 2012,
Wahlgren et al described an “exosome display technology
in vitro” in which, exogenous siRNAs were successfully
introduced into various kinds of human exosomes and
were used to deliver siRNA to human mononuclear blood
cells. Plasma exosomes effectively delivered the siRNA
into the target cells, causing selective gene silencing of
MAPK-1 [30]. Other strategies to exploit exosomes for
siRNA delivery in vitro and in vivo have also been re-
ported [25,31,32]. But, despite promising uses for exo-
somes as a delivery of exogenous RNA, to date, only a few
research reports on the subject were published.
The purpose of this study was to investigate the poten-
tial use of exosomes as a carrier for siRNA delivery
in vitro. Fluorescently labeled siRNAs were successfully
introduced into various kinds of human exosomes: con-
ventional siRNA was loaded with a chemical transfection
reagent (Lipofectamine) and self-delivering sdRNA with-
out any reagent. Both cultural and ascites-derived exo-
somes effectively delivered the hydrophobically modified
sdRNA or usual siRNA molecules into the different target
cells. This observation indicates the nonspecific ability of
the cells to capture alien vesicles. Taken together, the
results strongly suggest that the approaches used were
successful at introducing the heterologous siRNAs into
the exosomes and at delivery of heterologous siRNAs to
recipient cells via exosomes.
Next, we examined if exosome-delivered siRNA was
functional and caused post-transcriptional gene silencing
in recipient cells. The RAD51 gene was found to be
down-regulated in HeLa and HT1080 cells that had been
co-cultured with exosomes containing siRNA against the
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fectively delivered the siRNA against RAD51 into the
target cells, causing selective genes silencing and leading
to reproductive cancer cell death by knockdown of
RAD51. The effect of RAD51 gene knockdown was
equally visible in HeLa and in HT1080 cells. This indi-
cates approximately the same ability of these cancer cell
types to adsorb exosomes. Our results, and the results
published previously [30], show that chemical loading of
the exosomes to be used as siRNA delivery vector was
inapplicable as the excess of micelles (siRNA embedded
in lipid micelles) could not be separated from the exo-
somes. It is uncertain whether the exosomes or the ex-
cess of micelles deliver the nucleic acid of interest to
cells and, therefore, safe delivery of siRNA via exosomes
is not evident in the long term use this approach in vivo.
Thus, electroporation was examined as a means of intro-
ducing siRNA against RAD51 into exosomes. Survival of
HeLa cells after co-culturing with electroporated exo-
somes was used as a test system to optimize the trans-
fection. The results provide sufficient evidence that the
heterologous siRNA was quite effectively introduced into
exosomes using electroporation, but the method may
need to be optimized for each exosome and each cell
type.
Conclusions
We can assume that exosomes effectively deliver siRNA
into the target cells in vitro, causing selective genes
silencing and leading to reproductive cancer cell death
by knockdown of RAD51 recombinase. Taken together,
(i) exosomes may represent an efficient delivery platform
for siRNAs, (ii) siRNA-mediated induction of RNAi is a
promising approach for the knockdown of pathologically
relevant oncogenes, and (iii) delivery of siRNA via exo-
somes may become an attractive therapeutic strategy for
the treatment of cancer.
Methods
Exosome purification
For the generation of exosomes HeLa and HT1080 human
fibosarcoma cells were grown during 5 days in 30 ml
(250 sm2 flacks were used) of DMEM-F12 medium sup-
plemented with 10% fetal bovine serum (FBS) depleted
from exosomes as described [22]. On the day of collection,
the medium from the cells was removed (conditioned
medium). Exosomes were isolated by differential centri-
fugations and micro-filtration as previously described
[15,22]. Briefly, 100 ml of cell supernatants were har-
vested, centrifuged at 300 g for 10 min to eliminate cells
and then at 15 000 g for 30 min to remove cell debris.
Exosomes were pelleted by ultracentrifugation at 110
000 g for 70 min at 4°C. The exosome pellet was resus-
pended in 1 ml of DMEM medium by syringing three tofive times through a sterile 27-gauge needle to prevent the
exosomes from clumping together. Then the exosome
samples were filtered through a 0.22-μm filter for ste-
rilization. The protein content of the exosome suspension
was quantified using the Bradford reagent. Exosomes from
malighnant ascitic fluids (ascites) were prepared by dif-
ferential centrifugation and filtration as for HeLa and
HT1080 cells.
Atomic force microscopy (AFM)
Purified exosomes were diluted in de-ionized water and
adsorbed to freshly cleaved mica sheets, fixed with 0.5%
glutaraldehyde, rinsed with de-ionized water and air-
dried. The samples were scanned in the air by semi-
contact method with a scanning microscope of Solver
Bio series (NT-MDT, Russia) equipped with silicon test
probe (type NSG01), with a characteristic stiffness of
5.5 N/m and a typical radius of curvature of the tip (less
than 10 nm). The initial amplitude of scanning was set
to 16 nA in current terms; SetPoint was adjusted to half
of the amplitude. Scanning was performed with a fre-
quency of 1.01 Hz. The images were processed using
standard software package (Image Analysis Nova).
Loading of exosomes with siRNA
Two different methods, chemical treatment and electro-
poration, were used. For chemical loading of exosomes,
siRNA at a final concentration of 2 μmol/ml was mixed
with Lipofectamine transfection reagent in 100 μl of
siRNA buffer and incubated for 10 min at RT. Then
300 μl of exosome suspension was added and the mixture
was incubated for additional 30 min at RT. To remove the
excess of micelles, the exosomes were purified using three
to five times filtration through a 100-kDa filter (Amicon,
Millipore) with washing by cultural medium.
For electroporation assays exosomes derived from
HeLa, HT1080 or ascitic fluids were diluted in cytomix
transfection buffer. SiRNAs against RAD51 or RAD52 at
a final concentration of 2 μmol/ml were added to 300 μl
of exosome sample. The mixtures were transferred into
ice cold 0.4-cm cuvettes and electroporated at 0.7 kV
using 350 microsecond pulse 20 times by the Eppendorf
multiporator.
RNA duplexes targeting RAD51 or RAD52 (ON-TAR-
GETplus SMARTpool) were purchased from Dharmacon.
For control experiments fluorescently labeled conventio-
nal siRNA (Qiagen) and self-delivering siRNA (sdRNA)
were used. SdRNA, a hydrophobically modified siRNA for
cell transfection without formulation with Lipofectamine,
was kindly provided by Advirna, Cambridge MA.
Transfection of siRNA into cells via exosomes
For siRNAs exosome-delivery assays, HeLa and HT1080
cells were seeded in 24-well plates at a density of 0.5 ×
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exosomes loaded with siRNA were co-cultured with the
recipient cells in order to deliver the heterologous
siRNA. The cells, transfected with a fluorescently la-
beled siRNA, were trypsinized, then isolated, washed
three times with PBS and were analyzed by Confocal
microscopy (LEICA TCS SP5X) and Flow cytometry
(Beckman Coulter). All tissue culture reagents were
obtained from Invitrogen and Hyclone.
Protein detection
Dot blot was used to detect exosomal proteins HLA-ABC
and CD63 in exosome suspension after purification. Fif-
teen micrograms of exosome suspension were dropped
into nitrocellulose (NC) membranes (Millipore). The
membranes were dried, blocked with 5% nonfat dry milk,
washed in Tris-Buffered Saline with 0.1% Tween 20 buffer
(TBST) and probed with primary antibodies against HLA-
ABC (1:200 dilution) or CD63 (1:200 dilution). All the pri-
mary antibodies were obtained from Beckman Coulter.
After washing in TBST, membranes were incubated
with HRP-conjugated secondary antibody (antimouse
IgG: 1:10000; Sigma). For detection, enhanced chemilu-
minesence was carried out using the ECL plus kit (Amersham
Biosciences Corp).
The exosome-based delivery of siRNA to cells was
determined by Western Blot analysis and compared with
direct transfection of the same siRNA to cells. For expres-
sion analysis of RAD51 and RAD52 proteins whole cell
extracts were made by lysis of 1-5 × 106 cells in 30–50 μl
of lysis buffer (10 мМ Tris-HCl pH 7.4, 0.1% Triton
X-100, 5 мМ PMSF, 5 мМ MgCl2, 5 u/ml DNAse I,
20 мМ β-mercaptoethanol). For western analysis aliquots
of extracts containing equal amounts of total protein as
determined by Bradford reagent were used. Following
sonication and boiling, aliquots were resolved by 12%
SDS–PAGE according to Laemmli, transferred to a PVDF
membrane (Thermo Scientific) and hybridized with a
mouse monoclonal antibody against RAD51 at the 1:1000
dilution (clone 3C10, Invitrogen) or against RAD52 at the
1:1000 dilution (Thermo Scientific) followed by a peroxi-
dase-labeled anti-mouse antibody (Sigma) at the 1:10000
dilution. Antibody binding was detected by enhanced che-
moluminescence (Pierce). Equality of loading was con-
firmed by hybridizing with a monoclonal antibody against
GAPDH at the 1:10000 dilution (Clone: ZG003, Zymed).
Clonogenic survival assays
After treatment with exosomes loaded with siRNAs as
stated above the cells were cultured for several days.
After 5-7 days the plates were rinsed with PBS, stained
with methylene blue (0.25%) and visible colonies were
counted. The survival of the non-transfected cells was
assumed as 100%.Cell cycle analysis
For monitoring of cell cycle parameters 30–40% confluent
HeLa cells, seeded in a 35 mm diameter Petri dishes, were
incubated with exosomes loaded with RAD51 siRNA for
24–72 hours. After incubation, cells were trypsinized, cen-
trifuged at 200 g for 10 min, washed with PBS and then
stained with a dye solution (1 μg/ml Hoechst 33342, 0.1%
Triton X-100) for 10 min and subjected to flow cytometry
analysis. Except for RAD51 siRNA, the control cells were
subjected to the same experimental conditions.
Apoptosis assay
DiOC6(3)/PI staining was used to detect mitochondrial
membrane potential assessment and plasma membrane in-
tegrity. A total of 106 cells were diluted in 100 μl of PBS.
DiOC6(3) (Invitrogen) was added up to a final concentra-
tion of 20 nM. The tubes were then gently mixed and in-
cubated for 20 min in 5% CO2 atmosphere at 37°C. Then
the cells were washed with PBS, contained 2% of serum,
and PI (Propidium Iodide) was added up to a final concen-
tration of 1 μg/ml. Flow cytometry analysis was conducted
within 10 min. The data from 104 cells were collected and
analyzed using CellQuest Pro Software (Becton Dickinson)
to calculate the proportion of early apoptotic, late apop-
totic/dead and viable healthy cells.
The Vybrant Apoptosis Assay Kit (Molecular Probes)
was used to detect changes in plasma membrane perme-
ability to Yo-Pro-1 related to apoptosis. A total of 106 cells
were diluted in 1 ml of PBS; 1 μl of Yo-Pro-1 (100 μmol/l)
was added. The tubes were gently mixed and incubated for
20 min at RT and 6 μmol/l PI were added to each tube.
Flow cytometry analysis was conducted within 10 min.
Immunofluorescence analysis of RAD51 foci
Before irradiation HeLa cells were incubated for 48 h with
exosomes loaded with RAD51siRNA. Gamma irradiation
was performed with a 137Cs source. After irradiation at
10 Gy the cells were maintained for 6 h in the fresh
medium and then analyzed by immunofluorescence for
the presence of RAD51 foci. Immunofluorescence staining
was performed by 4% PFA fixation, 0.2% Triton X-100
treatment, blocking in 1% BSA plus 1% normal goat
serum and staining with first mouse monoclonal antibody
against RAD51 at the 1:200 dilution (clone 3C10, In-
vitrogen) and Alexa Fluor 594 secondary antibodies (Invi-
trogen). Except for RAD51 siRNA, the control cells were
subjected to the same experimental conditions.
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Additional file 1: Figure S1. siRNA transfection via exosomes resulted
in a substantial decrease of the protein expression level and in
suppression of RAD51 downstream activity. A, Western blot probed with
RAD51 and RAD52 in HeLa cells direct transfected with specific siRNAs
and with exosome carriers of siRNAs against RAD51 or RAD52. The cells
treated by Lipofectamine alone were analyzed as a control. Equality of
loading was confirmed by hybridizing with a monoclonal antibody
against GAPDH. B, Analysis of RAD51 recruitment in HeLa cells irradiated
with γ-rays. Representative pictures of RAD51 repair foci in HeLa cells at
6 h after irradiation with 10 Gy, control (left panel) and cells transfected
by RAD51 siRNA via exosomes (right panel).
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